Author of

• 13580

  +

  P1.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 233)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Biology, Pathology, and Molecular Testing
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13695

    +

    P1.04-115 - Chemoterapy and Targeted Therapy Sensitivity Testing in Malignant Pleural Effusions (ID 1643)

    09:30 - 09:30  |  Author(s): B. Gorgulu
    • Abstract

    Background:
    Clinical management of malignant pleural effusions (MPE) is a major problem in oncology with short survival. MPE is caused by various types of malignancies, especially lung, breast carcinomas, lymphomas besides ovarian carcinoma, malignant melanoma. Intrapleural chemotherapy might be a helpful treatment strategy in MPE cases. Intrapleural chemotherapy also enters systemic circulation and affects the primary tumor as well. The aim of this study is to evaluate ex vivo chemoterapy and targeted therapy sensitivity in MPE cases to project which drug might be effective.
    
    Methods:
    Effusion fluids from patients with MPE were fresh obtained. After centrifugation, the pellet was diluted in PBS and cell isolation was performed by Ficoll gradient to separate cells from erytrocytes. Cells were incubated in HITES supplemented complete RPMI medium at 37C with 5%CO2. After primary cell culture was obtained, cells were incubated to 96 well plates and agents ( Bevacuzimab, Cetuximab, Rituximab, Bortozemib, Gemsitabin, Vinblastin, Bleomycin, Docetaxel, 5 Florourasil, Cisplatin, Cyclophosphamide, Doxorubicine) in different dose ranges for 24 hours. WST-1 was performed to check cell viability.
    
    Results:
    The primary tumors of nine cases in this study with MPEs are breast carcinomas, lung adenocarcinoma, small cell carcinoma and mantle cell lymphoma. Resistance were observed in most drugs. Breast carcinoma cells and lung adenocarcinoma cells were sensitive to cisplatin and/or vinsblastin. Small cell carcinoma cells were sensitive to docetaxel and/ or bleomycin. Sensitivity was not observed to targeted therapy agents at single dose during 24 hours incubation.
    
    Conclusion:
    Our results indicate that ex vivo cancer cell culture and testing cell death results of various chemotherapoetic and new targeted drugs might help managing highly agressive disease of patients with MPE. Intrapleural chemotherapy application that is found sensitive by ex vivo tests might help patients.